Trial Profile
A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Furmonertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Aosaikang Pharmaceutical
- 07 Jun 2022 Results assessing efficacy and safety of ASK120067 in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2022 Primary endpoint (Objective response rate) has been met, according to Results published in the Journal of Thoracic Oncology.
- 01 Jun 2022 Status changed from recruiting to completed, according to Results published in the Journal of Thoracic Oncology.